Brokerages expect that Dynavax Technologies Co. (NASDAQ:DVAX) will report $3.55 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Dynavax Technologies’ earnings, with the highest sales estimate coming in at $4.10 million and the lowest estimate coming in at $3.00 million. Dynavax Technologies posted sales of $50,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 7,000%. The firm is expected to report its next quarterly earnings report after the market closes on Monday, November 5th.
According to Zacks, analysts expect that Dynavax Technologies will report full-year sales of $11.62 million for the current year, with estimates ranging from $7.96 million to $15.27 million. For the next financial year, analysts forecast that the company will report sales of $93.41 million, with estimates ranging from $88.23 million to $98.58 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.01). The company had revenue of $1.25 million for the quarter, compared to analyst estimates of $1.88 million. Dynavax Technologies had a negative return on equity of 72.31% and a negative net margin of 8,570.06%. The firm’s quarterly revenue was up 1094.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.41) earnings per share.
Several brokerages have commented on DVAX. Royal Bank of Canada lifted their target price on Dynavax Technologies to $26.00 and gave the stock an “outperform” rating in a report on Monday, October 22nd. BidaskClub raised Dynavax Technologies from a “strong sell” rating to a “sell” rating in a report on Thursday, October 11th. ValuEngine downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Monday, July 30th. Cantor Fitzgerald set a $30.00 target price on Dynavax Technologies and gave the stock a “buy” rating in a report on Friday, October 19th. Finally, Zacks Investment Research raised Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $28.25.
Several hedge funds have recently bought and sold shares of DVAX. Eagle Asset Management Inc. bought a new position in shares of Dynavax Technologies in the 2nd quarter worth about $35,054,000. PointState Capital LP bought a new stake in Dynavax Technologies in the 2nd quarter valued at about $28,800,000. Carillon Tower Advisers Inc. bought a new stake in Dynavax Technologies in the 2nd quarter valued at about $24,951,000. Senvest Management LLC increased its position in Dynavax Technologies by 52.7% in the 2nd quarter. Senvest Management LLC now owns 2,336,089 shares of the biopharmaceutical company’s stock valued at $35,625,000 after buying an additional 806,102 shares in the last quarter. Finally, Chicago Capital LLC increased its position in Dynavax Technologies by 48.3% in the 2nd quarter. Chicago Capital LLC now owns 1,294,104 shares of the biopharmaceutical company’s stock valued at $19,735,000 after buying an additional 421,446 shares in the last quarter. 82.23% of the stock is owned by hedge funds and other institutional investors.
Shares of DVAX opened at $10.83 on Friday. The stock has a market cap of $632.42 million, a price-to-earnings ratio of -6.26 and a beta of 0.29. Dynavax Technologies has a 12 month low of $9.63 and a 12 month high of $23.85. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
See Also: Why do corrections happen?
Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.